Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Can Trulicity® (dulaglutide) be used in the pediatric and adolescent population?
Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adult and pediatric patients 10 years and older with type 2 diabetes.
AWARD-PEDS
AWARD-PEDS was a phase 3, randomized, placebo-controlled study that assessed the efficacy and safety of dulaglutide 0.75 mg and 1.5 mg in pediatric patients, ages 10 to less than 18 years old, with inadequately controlled type 2 diabetes despite diet and exercise, with or without metformin and/or basal insulin.1
The primary endpoint of AWARD-PEDS was to show superiority of dulaglutide (0.75 mg and 1.5 mg, pooled doses) versus placebo for change in glycated hemoglobin (HbA1c) at 26 weeks.1
Key inclusion criteria for AWARD-PEDS is displayed in Key Inclusion Criteria for AWARD-PEDS.1
Patient Population |
Diagnosis |
Current Therapy |
Baseline HbA1c |
Children 10-17 y of age |
Type 2 diabetes |
Diet and exercise with or without metformin and/or basal insulin at stable doses for at least 8 weeks |
>6.5% and ≤11% |
Newly diagnosed and not on any medication |
>6.5% and ≤9% |
Abbreviations: AWARD-PEDS = Assessment of Weekly AdministRation of LY2189265 in Diabetes – PEDiatric Study; HbA1c = glycated hemoglobin.
Reference
1Arslanian SA, Hannon T, Zeitler P, et al; AWARD-PEDS Investigators. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022;387(5):433-443. https://doi.org/10.1056/NEJMoa2204601
Date of Last Review: 02 June 2022